These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 16619561)
21. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer. Schippinger W; Regitnig P; Bauernhofer T; Ploner F; Hofmann G; Krippl P; Wehrschütz M; Lax S; Carney W; Neumann R; Wernecke KD; Samonigg H Oncol Rep; 2004 Jun; 11(6):1331-6. PubMed ID: 15138574 [TBL] [Abstract][Full Text] [Related]
22. Analysis of the prognostic value of soluble epidermal growth factor receptor plasma concentration in advanced non-small-cell lung cancer patients. Jantus-Lewintre E; Sirera R; Cabrera A; Blasco A; Caballero C; Iranzo V; Rosell R; Camps C Clin Lung Cancer; 2011 Sep; 12(5):320-7. PubMed ID: 21729651 [TBL] [Abstract][Full Text] [Related]
23. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer. Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215 [TBL] [Abstract][Full Text] [Related]
24. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. Konecny GE; Thomssen C; Lück HJ; Untch M; Wang HJ; Kuhn W; Eidtmann H; du Bois A; Olbricht S; Steinfeld D; Möbus V; von Minckwitz G; Dandekar S; Ramos L; Pauletti G; Pegram MD; Jänicke F; Slamon DJ J Natl Cancer Inst; 2004 Aug; 96(15):1141-51. PubMed ID: 15292386 [TBL] [Abstract][Full Text] [Related]
25. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Lipton A; Leitzel K; Ali SM; Demers L; Harvey HA; Chaudri-Ross HA; Evans D; Lang R; Hackl W; Hamer P; Carney W Cancer; 2005 Jul; 104(2):257-63. PubMed ID: 15952182 [TBL] [Abstract][Full Text] [Related]
26. Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Hudelist G; Köstler WJ; Gschwantler-Kaulich D; Czerwenka K; Kubista E; Müller R; Helmy S; Manavi M; Zielinski CC; Singer CF Eur J Cancer; 2006 Jan; 42(2):186-92. PubMed ID: 16326100 [TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer. Fehm T; Jäger W; Krämer S; Sohn C; Solomayer E; Wallwiener D; Gebauer G Anticancer Res; 2004; 24(3b):1987-92. PubMed ID: 15274389 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism. Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656 [TBL] [Abstract][Full Text] [Related]
29. HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support. Bewick M; Conlon M; Gerard S; Lee H; Parissenti AM; Zhang L; Glück S; Lafrenie RM Bone Marrow Transplant; 2001 Apr; 27(8):847-53. PubMed ID: 11477443 [TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
31. [Serum her-2/neu level and related factors in patients with breast cancer]. Yuan P; Xu BH; Zhang C; Qi J Zhonghua Zhong Liu Za Zhi; 2003 Nov; 25(6):573-4. PubMed ID: 14690565 [TBL] [Abstract][Full Text] [Related]
32. p53 as a specific prognostic factor in triple-negative breast cancer. Chae BJ; Bae JS; Lee A; Park WC; Seo YJ; Song BJ; Kim JS; Jung SS Jpn J Clin Oncol; 2009 Apr; 39(4):217-24. PubMed ID: 19304743 [TBL] [Abstract][Full Text] [Related]
33. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019 [TBL] [Abstract][Full Text] [Related]
34. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. Li X; Lewis MT; Huang J; Gutierrez C; Osborne CK; Wu MF; Hilsenbeck SG; Pavlick A; Zhang X; Chamness GC; Wong H; Rosen J; Chang JC J Natl Cancer Inst; 2008 May; 100(9):672-9. PubMed ID: 18445819 [TBL] [Abstract][Full Text] [Related]
35. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115 [TBL] [Abstract][Full Text] [Related]
36. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951 [TBL] [Abstract][Full Text] [Related]
37. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038 [TBL] [Abstract][Full Text] [Related]
38. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Torrisi R; Balduzzi A; Ghisini R; Rocca A; Bottiglieri L; Giovanardi F; Veronesi P; Luini A; Orlando L; Viale G; Goldhirsch A; Colleoni M Cancer Chemother Pharmacol; 2008 Sep; 62(4):667-72. PubMed ID: 18064460 [TBL] [Abstract][Full Text] [Related]
39. EGFR activity in HER-2 over-expressing metastatic breast cancer: evidence for simultaneous phosphorylation of Her-2/neu and EGFR. Gschwantler-Kaulich D; Hudelist G; Koestler WJ; Czerwenka K; Mueller R; Helmy S; Ruecklinger E; Kubista E; Singer CF Oncol Rep; 2005 Aug; 14(2):305-11. PubMed ID: 16012707 [TBL] [Abstract][Full Text] [Related]
40. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer]. Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]